Clinical pathways becoming widespread

Payers who intend to improve patient outcomes while decreasing inappropriate drug utilization in oncology care are positioned to implement clinical pathways now more than ever before.

Prior authorization is a commonly used management strategy that is effective to a certain degree, but there is still room for improvement. Payers and practitioners alike agree that the ideal management strategy should enable practitioners to take the wheel in selecting a patient’s pharmacotherapy, which prior authorization can inhibit.

Clinical pathways can help to reduce the need for prior authorization as a management strategy while satisfying oncologists’ needs. The figure “Pathways to prior authorization goals” shows how goals of prior authorization can be met by clinical pathways.

The 50% of plans across the nation that have already implemented pathways or plan to do so soon see that the greatest return on investment of clinical pathways is for cancer diagnoses that are most prevalent and/or are associated with the highest drug cost.

The figure below shows the most common tumor types for which pathways have been developed by health plans.

Tumor types that are most often addressed by clinical pathways

Proportion of payers

Source: “Payers Working Collaboratively With Providers to Adopt Clinical Pathways and New Care Delivery Models,” Journal of Oncology Practice, Vol. 9, issue 2


PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for September 2014



Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Hospitals Struggle With ACA Challenges

Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements

Schizophrenia: Overview and Treatment Options


Schizophrenia Therapy Options Increasing



Too Many Abandon the “Second Victims” of Medical Errors


New Controversy for 340B: OPA Rebuffs Ruling by Court

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update


Loxapine Inhalation Powder (Adasuve)